Literature DB >> 19841187

Human late memory CD8+ T cells have a distinct cytokine signature characterized by CC chemokine production without IL-2 production.

Tae Kon Kim1, Lisa S St John, Eric D Wieder, Jahan Khalili, Qing Ma, Krishna V Komanduri.   

Abstract

Late memory T cell skewing is observed in the setting of immune recovery after cord blood transplantation, and may be associated with inferior control of viral reactivation and cancers. Therefore, we sought to understand how late memory cells differ functionally from earlier stage memory T cells, and whether surface phenotypes associated with differentiation stages were predictably associated with functional signatures. Higher order cytokine flow cytometry allows characterization of human T cells based on complex phenotypic markers and their differential capacity to simultaneously secrete effector proteins, including cytokines and chemokines. We used 8-color, 10-parameter cytokine flow cytometry to characterize the functional activation of human late memory CD8(+) T cells defined by CD45RA and CD27 expression (CD27(-)CD45RA(+)). We assessed the 15 possible functional signatures of cells defined by production of IL-2, IFN-gamma, TNF-alpha, and MIP-1beta alone or in combination, following activation with Ags stimulating bypassing surface proteins (PMA:ionomycin) or through the TCR (e.g., viral Ags). Late memory CD8(+) T cells produced abundant amounts of CC chemokines (MIP-1beta, MIP-1alpha, and RANTES) but not IL-2. IL-2/IFN-gamma coproduction, characteristic of protective immune responses to viral infections, was absent in late memory CD8(+) T cells. These data demonstrate that functional cytokine signatures are predictably associated with CD8(+) maturation stages, and that the polarization of late memory CD8(+) T cells toward CC chemokine production and away from IL-2 production suggests a unique functional role for this subset.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19841187     DOI: 10.4049/jimmunol.0902068

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

Review 1.  Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

Authors:  Richard Wu; Marie-Andrée Forget; Jessica Chacon; Chantale Bernatchez; Cara Haymaker; Jie Qing Chen; Patrick Hwu; Laszlo G Radvanyi
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

2.  MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner.

Authors:  Takero Shindo; Tae Kon Kim; Cara L Benjamin; Eric D Wieder; Robert B Levy; Krishna V Komanduri
Journal:  Blood       Date:  2013-04-10       Impact factor: 22.113

3.  Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients.

Authors:  Corinna La Rosa; Ajit P Limaye; Aparna Krishnan; Gideon Blumstein; Jeff Longmate; Don J Diamond
Journal:  Transpl Int       Date:  2011-06-14       Impact factor: 3.782

4.  Kinetics of effector functions and phenotype of virus-specific and γδ T lymphocytes in primary human cytomegalovirus infection during pregnancy.

Authors:  Chiara Fornara; Daniele Lilleri; M Grazia Revello; Milena Furione; Maurizio Zavattoni; Elisa Lenta; Giuseppe Gerna
Journal:  J Clin Immunol       Date:  2011-08-17       Impact factor: 8.317

5.  Reduced frequencies of polyfunctional CMV-specific T cell responses in infants with congenital CMV infection.

Authors:  Laura Gibson; Constance M Barysauskas; Margaret McManus; Sheryl Dooley; Daniele Lilleri; Donna Fisher; Tumul Srivastava; Don J Diamond; Katherine Luzuriaga
Journal:  J Clin Immunol       Date:  2015-02-25       Impact factor: 8.317

6.  Cutting edge: Virus-specific CD8+ T cell clones and the maintenance of replicative function during a persistent viral infection.

Authors:  Oliver Bannard; Matthew Kraman; Douglas T Fearon
Journal:  J Immunol       Date:  2010-11-10       Impact factor: 5.422

Review 7.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

8.  No evidence for TSLP pathway activity in human breast cancer.

Authors:  Cristina Ghirelli; Benjamin Sadacca; Fabien Reyal; Raphaël Zollinger; Paula Michea; Philémon Sirven; Lucia Pattarini; Carolina Martínez-Cingolani; Maude Guillot-Delost; André Nicolas; Alix Scholer-Dahirel; Vassili Soumelis
Journal:  Oncoimmunology       Date:  2016-05-09       Impact factor: 8.110

Review 9.  The evolving art of hematopoietic stem cell transplantation: translational research in post-transplant immune reconstitution and immunosuppression.

Authors:  Krishna V Komanduri; Eric D Wieder; Cara L Benjamin; Robert B Levy
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

10.  Diverse specificities, phenotypes, and antiviral activities of cytomegalovirus-specific CD8+ T cells.

Authors:  S E Jackson; G M Mason; G Okecha; J G P Sissons; M R Wills
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.